You don't have permission to view this recording. Please log in or use your personalized link.
Tasha Armour founder and CEO of Rare Ovarian Cancer Incorporated – ROC Inc. talks to three leading international experts on Granulosa Cell Tumours GCT.

Dr Simon Chu research head of Hormone Cancer Therapeutic Laboratory at the Hudson Institute of Medical Research.

Professor Peter Fuller AM is physician-scientist who leads the Centre for Endocrinology and Metabolism at the Hudson Institute of Medical Research. Head of Endocrinology Unit, Monash Health

Professor Tom Jobling OAM, Director of Gynaecology Oncology at Monash Health

Granulosa Cell Tumour GCT has two subtypes adult aGCT and juvenile jGCT this is an opportunity to hear about what the latest developments for both of these subtypes and what is the future direction is for research and treatment for all GCT.
  • 1582553029-041d95a32ea2994d
    Tasha Armour
    ROCInc Founder and CEO
  • 1582617320-0cad8ceff46adafd
    Professor Peter Fuller
    Head, Endocrinology Unit, Monash Health Centre for Endocrinology and Metabolism. Hudson Institute of Medical Research
  • 1582722274-2f1249d724081996
    Dr Simon Chu
    Research Head of Hormone Cancer Therapeutic Laboratory. Hudson Institute of Medical Research
  • 1582722298-5a14a88671f9e5df
    Professor Tom Jobling
    Director of Gynaecology Oncology . Monash Health